Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Non-Current Assets (2016 - 2025)

Traws Pharma (TRAW) has disclosed Non-Current Assets for 14 consecutive years, with $2.6 million as the latest value for Q4 2025.

  • For Q4 2025, Non-Current Assets rose 23881.82% year-over-year to $2.6 million; the TTM value through Dec 2025 reached $5.9 million, up 10098.28%, while the annual FY2025 figure was $2.6 million, 23881.82% up from the prior year.
  • Non-Current Assets hit $2.6 million in Q4 2025 for Traws Pharma, down from $2.8 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $2.8 million in Q3 2025 and bottomed at $11000.0 in Q4 2024.
  • Average Non-Current Assets over 5 years is $334450.0, with a median of $35000.0 recorded in 2022.
  • Year-over-year, Non-Current Assets plummeted 77.84% in 2022 and then skyrocketed 23881.82% in 2025.
  • Traws Pharma's Non-Current Assets stood at $48000.0 in 2021, then plummeted by 47.92% to $25000.0 in 2022, then decreased by 8.0% to $23000.0 in 2023, then plummeted by 52.17% to $11000.0 in 2024, then surged by 23881.82% to $2.6 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $2.6 million, $2.8 million, and $252000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.